We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Joerg Herrmann

Joerg Herrmann MD

Professor of Medicine, Mayo Graduate School of Medicine, Rochester, Minnesota

Biographical Sketch:

Dr. Joerg Herrmann received his medical training at Ruhr University, Bochum, Germany, and completed his internship in internal medicine at the University Clinic in Essen. Following a postdoctoral research fellowship, he pursued the clinician–investigator track in internal medicine-cardiology, and further training in interventional cardiology at the Mayo Clinic, Rochester, Minnesota. He then joined the staff of the Department of Cardiovascular Diseases at the Mayo Clinic, Rochester. Currently he is an Associate Professor of Medicine at the Mayo Graduate School of Medicine and serves as the director of the Cardio-Oncology Clinic and the research director of the Ischemic Heart Disease program. 

Dr. Herrmann has been receiving NIH research funding, serves as a reviewer for over 30 journals, including all major cardiovascular journals. He is also a contributor to Braunwald’s Heart Disease, the associated editor of Trends in Cardiovascular Medicine, and is the editor of the textbook Clinical Cardio-Oncology. 

His main research interests are cardio-oncology, cardiac biomarkers, periprocedural myocardial infarction, atherosclerosis, and vascular biology.

Disclosures

Dr. Joerg Herrmann participated in the 2014 and 2016 Ponatinib in CML Cardio-Oncology Advisory Board meeting organized by ARIAD Pharmaceuticals, the 2016 Carfilzomib Advisory Board meeting organized by Amgen and is a member of the Institute for Cardio-Oncology advisory panel sponsored by Bristol-Myers Squib.

Recent Contributions to PracticeUpdate:

  1. Nonculprit Lesion Severity and Outcome of Revascularization in Patients With STEMI and Multivessel Coronary Disease
  2. 10-Year Outcomes From a Randomized Trial of Polymer-Free vs Durable Polymer Drug-Eluting Coronary Stents
  3. New Cardiac Abnormalities Following Radiation Therapy in Breast Cancer Patients Treated With Trastuzumab
  4. PCI vs CABG in the Treatment of Unprotected Left Main Stenosis
  5. AMI Treatment and Outcomes in 6.5 Million Patients With a Current or Historical Diagnosis of Cancer
  6. 2019 Top Stories in Cardiology: Time for Shortcuts After PCI?
  7. Efficacy and Safety of Stents in STEMI
  8. AHA Scientific Sessions 2019: Recommendations From Dr. Joerg Herrmann
  9. Physiological Assessment of Residual Ischemia After Successful Angiographic PCI
  10. Bleeding and New Cancer Diagnosis in Patients With Atherosclerosis

Most Read This Week

Recently Updated